Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerry Taylor

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|July 16, 2009
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemiaEnrique Hernandez, Peter Ganly, Veena Charu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 24, 2013
Reducing the risk of harm from intravenous potassium: a multi-factorial approach in the haematology settingMichael Barras, Diana Moore, Daniel Pocock, et al.
Current Medical Research and Opinion|June 15, 2007
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemiaDusan Kotasek, Jean-Luc Canon, Maria Victoria Mateos, et al.
Internal Medicine Journal|November 19, 2021
Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issueKarthik Nath, Thomas Wong, Ajit Ahluwalia, et al.
International Journal of Environmental Research and Public Health|February 25, 2022
The Association between Diabetes and Human T-Cell Leukaemia Virus Type-1 (HTLV-1) with <i>Strongyloides stercoralis</i>: Results of a Community-Based, Cross-Sectional Survey in Central AustraliaMohammad Radwanur Talukder, Hai Pham, Richard Woodman, et al.
Leukemia & Lymphoma|August 3, 2002
Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis--a missed opportunity for induction CNS prophylaxisJeremy Wellwood, Kerry Taylor, Susan Wright, et al.
Plos Neglected Tropical Diseases|December 8, 2021
Very high prevalence of infection with the human T cell leukaemia virus type 1c in remote Australian Aboriginal communities: Results of a large cross-sectional community surveyLloyd Einsiedel, Hai Pham, Mohammad Radwanur Talukder, et al.
British Journal of Haematology|October 3, 2002
Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignanciesMichael Hedenus, Sören Hansen, Kerry Taylor, et al.
Disability and Rehabilitation|February 25, 2020
Environmental and systemic challenges to delivering services for Aboriginal adults with a disability in Central AustraliaJohn Gilroy, Angela Dew, Rebecca Barton, et al.
Leukemia & Lymphoma|October 21, 2003
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphomaAndrew Grigg, Philippe Solal-Celigny, Peter Hoskin, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|July 16, 2009
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemiaEnrique Hernandez, Peter Ganly, Veena Charu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 24, 2013
Reducing the risk of harm from intravenous potassium: a multi-factorial approach in the haematology settingMichael Barras, Diana Moore, Daniel Pocock, et al.
Current Medical Research and Opinion|June 15, 2007
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemiaDusan Kotasek, Jean-Luc Canon, Maria Victoria Mateos, et al.
Internal Medicine Journal|November 19, 2021
Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issueKarthik Nath, Thomas Wong, Ajit Ahluwalia, et al.
International Journal of Environmental Research and Public Health|February 25, 2022
The Association between Diabetes and Human T-Cell Leukaemia Virus Type-1 (HTLV-1) with <i>Strongyloides stercoralis</i>: Results of a Community-Based, Cross-Sectional Survey in Central AustraliaMohammad Radwanur Talukder, Hai Pham, Richard Woodman, et al.
Leukemia & Lymphoma|August 3, 2002
Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis--a missed opportunity for induction CNS prophylaxisJeremy Wellwood, Kerry Taylor, Susan Wright, et al.
Plos Neglected Tropical Diseases|December 8, 2021
Very high prevalence of infection with the human T cell leukaemia virus type 1c in remote Australian Aboriginal communities: Results of a large cross-sectional community surveyLloyd Einsiedel, Hai Pham, Mohammad Radwanur Talukder, et al.
British Journal of Haematology|October 3, 2002
Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignanciesMichael Hedenus, Sören Hansen, Kerry Taylor, et al.
Disability and Rehabilitation|February 25, 2020
Environmental and systemic challenges to delivering services for Aboriginal adults with a disability in Central AustraliaJohn Gilroy, Angela Dew, Rebecca Barton, et al.
Leukemia & Lymphoma|October 21, 2003
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphomaAndrew Grigg, Philippe Solal-Celigny, Peter Hoskin, et al.
Pageof 8